Sunday, 22 April 2018

Glenmark initiates myeloma drug trial

08 December 2017 | News

GBR 1342 is an investigational new drug from the company's immuno-oncology portfolio.

Image credit- covance blog

Image credit- covance blog

Glenmark Pharma has initiated the phase-1 clinical trial of GBR 1342, an investigational antibody for treatment of multiple myeloma.

GBR 1342 is an investigational new drug from the company's immuno-oncology portfolio.

Glenmark had received clearance from US health regulator in May this year, for the investigational new drug application to initiate phase-1 study of GBR 1342.

This first-in-human, open-label study's primary objective is to assess the safety and tolerability of increasing doses of GBR 1342 in multiple myeloma patients until a maximum tolerated dose is reached.

The additional study objectives include assessment of biomarkers, immunogenicity and additional measures of anti- tumour activity.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account





Survey Box

Can access to vaccines reduce the threat of antibiotic resistance?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls